{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:39:30Z","timestamp":1792611570150,"version":"4.5.0"},"reference-count":293,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.nefroe.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:09:22Z","timestamp":1737691762000},"page":"15-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-6973","authenticated-orcid":false,"given":"Enrique","family":"Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"R\u00faa-Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Callejas Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"\u00c1vila Bernab\u00e9u","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda C.","family":"Cid Xutgla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Fern\u00e1ndez Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Mena-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"R\u00edos Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Manrique Escola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Javier","family":"Narv\u00e1ez Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Sope\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Quintana Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Romero-Yuste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Solans Laqu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2025.01.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102716","article-title":"The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis","volume":"20","author":"Guchelaar","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5152\/eujrheum.2022.20248","article-title":"Updates in ANCA-associated vasculitis","volume":"9","author":"Ross","year":"2022","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0015","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/rheumatology\/keac623","article-title":"Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice","volume":"62","author":"Chevet","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00325481.2022.2102368","article-title":"ANCA associated vasculitis (AAV): a review for internists","volume":"135","author":"Yaseen","year":"2023","journal-title":"Postgrad Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0025","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0030","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0040","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/art.1780330812","article-title":"The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary","volume":"33","author":"Fries","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0045","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/art.1780330803","article-title":"The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods","volume":"33","author":"Bloch","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0050","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener\u2019s granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0055","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/rheumatology\/kex075","article-title":"Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?","volume":"56","author":"Seeliger","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0060","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3349\/ymj.2022.0435","article-title":"Comparison of the 2022 ACR\/EULAR classification criteria for antineutrophil cytoplasmic antibody-associated vasculitis with previous criteria","volume":"64","author":"Pyo","year":"2023","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0075","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/art.41983","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"74","author":"Suppiah","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0080","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0085","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/ndt\/12.9.1863","article-title":"Rapid screening assay for anti-GBM antibody and ANCAs; an important tool for the differential diagnosis of pulmonary renal syndromes","volume":"12","author":"Westman","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0090","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1744-9987.2005.00319.x","article-title":"Complications of therapeutic plasma exchange: experience with 4857 treatments","volume":"9","author":"Basic-Jukic","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.ajkd.2012.02.330","article-title":"Bleeding complications of native kidney biopsy: a systematic review and meta-analysis","volume":"60","author":"Corapi","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0100","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/ndt\/16.5.953","article-title":"Renal histopathology and clinical course in 94 patients with Wegener\u2019s granulomatosis","volume":"16","author":"Aasar\u00f8d","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0105","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0110","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/ckj\/sfaa073","article-title":"Long-term validation of the renal risk score for vasculitis in a Southern European population","volume":"14","author":"Villacorta","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0115","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfab250","article-title":"Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"37","author":"Casal Moura","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0120","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1681\/ASN.2021060771","article-title":"Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges","volume":"33","author":"Nezam","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2500\/ajra.2012.26.3825","article-title":"Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener\u2019s granulomatosis presenting primarily with sinonasal disease","volume":"26","author":"Borner","year":"2012","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00000478-199006000-00006","article-title":"Interpretation of head and neck biopsies in Wegener\u2019s granulomatosis. A pathologic study of 126 biopsies in 70 patients","volume":"14","author":"Devaney","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40120-021-00315-7","article-title":"ANCA-associated vasculitic neuropathies: a review","volume":"11","author":"Koike","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/rheumatology\/keaa233","article-title":"Muscle biopsy in anti-neutrophil cytoplasmic antibody-associated vasculitis: diagnostic yield depends on anti-neutrophil cytoplasmic antibody type, sex and neutrophil count","volume":"60","author":"Lacou","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0145","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.autrev.2010.07.009","article-title":"Microscopic polyangiitis: clinical presentation","volume":"9","author":"Villiger","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0150","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/ijd.16247","article-title":"Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation","volume":"61","author":"Gibson","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0155","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-associated vasculitis: core curriculum 2020","volume":"75","author":"Geetha","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0160","first-page":"1467","article-title":"Type of ANCA may be indispensable in distinguishing subphenotypes of different clinical entities in ANCA-associated vasculitis","volume":"12","author":"Konstantouli","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0165","article-title":"Do relapses follow ANCA rises? A systematic review and meta-analysis on the value of serial ANCA level evaluation","volume":"9","author":"Al-Soudi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0170","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","article-title":"Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis","volume":"72","author":"Mahr","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0175","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003113","article-title":"Diagnostic significance of antineutrophil cytoplasmic antibody (ANCA) titres: a retrospective case-control study","volume":"9","author":"Merindol","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103100","article-title":"Performance of MPO-ANCA and PR3-ANCA immunoassays for the stratification of specific ANCA-associated vasculitis: a systematic review and meta-analysis","volume":"21","author":"Walker","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0185","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","article-title":"ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients","volume":"12","author":"Cornec","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00296-022-05192-3","article-title":"Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis","volume":"43","author":"Mehta","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0195","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/ndt\/gfaa066","article-title":"PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab","volume":"36","author":"van Dam","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0200","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s40620-019-00628-9","article-title":"Update on ANCA-associated vasculitis: from biomarkers to therapy","volume":"32","author":"Tedesco","year":"2019","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0205","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MD.0b013e3181c101cc","article-title":"Persistent hematuria after induction of remission in Wegener granulomatosis: a therapeutic dilemma","volume":"88","author":"Magrey","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0210","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.kint.2023.02.029","article-title":"Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis","volume":"103","author":"Benichou","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2012.313","article-title":"Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"83","author":"Gou","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0220","doi-asserted-by":"crossref","first-page":"586","DOI":"10.34067\/KID.0006432020","article-title":"Biomarkers in ANCA-associated vasculitis: potential pitfalls and future prospects","volume":"2","author":"Morris","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0225","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12882-018-0992-4","article-title":"Neutrophil to lymphocyte ratio at diagnosis can estimate vasculitis activity and poor prognosis in patients with ANCA-associated vasculitis: a retrospective study","volume":"19","author":"Ahn","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0230","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/rheumatology\/ken500","article-title":"Circulating neutrophil gelatinase-associated lipocalin: a useful biomarker for assessing disease activity of ANCA-associated vasculitis","volume":"48","author":"Chen","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0235","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.medcli.2020.07.036","article-title":"Serum cytokines in ANCA-associated vasculitis: correlation with disease-related clinical and laboratory findings","volume":"157","author":"Krajewska Wojciechowska","year":"2021","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0240","first-page":"671","article-title":"Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis","volume":"87","author":"Luqmani","year":"1994","journal-title":"QJM"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0245","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham Vasculitis Activity Score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0255","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0260","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/ckj\/sfw056","article-title":"Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis","volume":"9","author":"Draibe","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0265","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3899\/jrheum.100074","article-title":"B cell abnormalities in Wegener\u2019s granulomatosis and microscopic polyangiitis: role of CD25+-expressing B cells","volume":"37","author":"Eriksson","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0270","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ekir.2020.11.016","article-title":"Circulating B cells, plasma cells, and Treg associate with ANCA levels in ANCA-associated vasculitis","volume":"6","author":"Manrique","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0275","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40620-017-0445-3","article-title":"Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome","volume":"31","author":"Crnogorac","year":"2018","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0280","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/annrheumdis-2012-201981","article-title":"Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis","volume":"72","author":"Monach","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0285","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ndt\/gfy300","article-title":"Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"35","author":"Moran","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0290","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1681\/ASN.2015050511","article-title":"Urinary soluble CD163 in active renal vasculitis","volume":"27","author":"O\u2019Reilly","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0295","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ndt\/gfy018","article-title":"Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study","volume":"34","author":"Dekkema","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0300","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0305","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0310","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0315","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/rheumatology\/keq400","article-title":"A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis","volume":"50","author":"Suppiah","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0320","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/art.1780400222","article-title":"Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides","volume":"40","author":"Exley","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0325","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","article-title":"Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients","volume":"44","author":"Gayraud","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0330","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/ard.2008.097758","article-title":"Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis","volume":"68","author":"Merkel","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0335","first-page":"448","article-title":"Relapses in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: likely to begin with the same organ as initial onset","volume":"35","author":"Chen","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0340","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.3899\/jrheum.121473","article-title":"New features of disease after diagnosis in 6 forms of systemic vasculitis","volume":"40","author":"Grayson","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0345","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","article-title":"Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis","volume":"143","author":"Hogan","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0350","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0355","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0360","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0365","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1053\/j.ajkd.2009.09.031","article-title":"Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series","volume":"55","author":"Bantis","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0370","first-page":"127","article-title":"ANCA and predicting relapse in systemic vasculitis","volume":"88","author":"Jayne","year":"1995","journal-title":"QJM"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0375","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.04160417","article-title":"The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis","volume":"13","author":"Rhee","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0380","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/art.39637","article-title":"Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3","volume":"68","author":"Fussner","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0385","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management","volume":"26","author":"Groh","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0390","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2215\/CJN.02500317","article-title":"ANCA glomerulonephritis and vasculitis","volume":"12","author":"Jennette","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0395","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0400","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0405","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0410","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0415","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.berh.2018.10.001","article-title":"Clinical features and structured clinical evaluation of vasculitis","volume":"32","author":"Ponte","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0420","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00296-017-3855-6","article-title":"Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"38","author":"Robson","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0425","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0430","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3899\/jrheum.161139","article-title":"OMERACT endorsement of patient-reported outcome instruments in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"44","author":"Robson","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0435","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2017-212713","article-title":"Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire","volume":"77","author":"Robson","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0440","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ajcp\/111.4.507","article-title":"International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA)","volume":"111","author":"Savige","year":"1999","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102618","article-title":"2020 international consensus on ANCA testing beyond systemic vasculitis","volume":"19","author":"Moiseev","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0450","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0455","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0460","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","article-title":"Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial","volume":"78","author":"Jones","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0465","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.1780391020","article-title":"Clinical features and therapeutic management of subglottic stenosis in patients with Wegener\u2019s granulomatosis","volume":"39","author":"Langford","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0470","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1177\/0961203308089693","article-title":"Clinical features and therapeutic management of subglottic stenosis in patients with Wegener\u2019s granulomatosis","volume":"17","author":"Solans-Laqu\u00e9","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0475","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1093\/rheumatology\/kez217","article-title":"Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis","volume":"58","author":"Quinn","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0480","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001088","article-title":"Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegener\u2019s): a report on 26 cases","volume":"94","author":"Girard","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0485","first-page":"1017","article-title":"Treatment of subglottic stenosis, due to Wegener\u2019s granulomatosis, with intralesional corticosteroids and dilation","volume":"30","author":"Hoffman","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0490","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejcts.2009.11.056","article-title":"Bronchoscopic balloon dilatation of tracheobronchial stenosis: long-term follow-up","volume":"38","author":"Shitrit","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0495","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/01945998211004264","article-title":"Factors affecting dilation interval in patients with granulomatosis with polyangiitis-associated subglottic and glottic stenosis","volume":"165","author":"Chen","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0500","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jamaoto.2016.3484","article-title":"Reconstructive techniques for the saddle nose deformity in granulomatosis with polyangiitis: a systematic review","volume":"143","author":"Ezzat","year":"2017","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0505","doi-asserted-by":"crossref","DOI":"10.1177\/2050312120936731","article-title":"The role of surgery in antineutrophil cytoplasmic antibody-associated vasculitides affecting the nose and sinuses: a systematic review","volume":"8","author":"Pendolino","year":"2020","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0510","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/BOR.0b013e328333e9e9","article-title":"Surgical interventions and local therapy for Wegener\u2019s granulomatosis","volume":"22","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0515","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/ard.2006.062711","article-title":"EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"66","author":"Hellmich","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0520","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0525","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s13023-020-01621-3","article-title":"French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)","volume":"15","author":"Terrier","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0530","unstructured":"Chalisey A, Karim M. Guidelines for the Management of ANCA-Associated Vasculitis with Renal Involvement. Norfolk and Norwich University Hospitals NHS Foundation Trust. [Internet], [Accessed 11 November 2023]. Available from: https:\/\/www.nnuh.nhs.uk\/publication\/guidelines-for-the-management-of-anca-associated-vasculitis-v1-2\/."},{"key":"10.1016\/j.nefroe.2025.01.001_bib0535","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0540","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0545","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/acr2.11274","article-title":"Comparison of two rituximab induction regimens for antineutrophil cytoplasm antibody-associated vasculitis: systematic review and meta-analysis","volume":"3","author":"B\u00e9nard","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0550","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0555","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0560","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0565","unstructured":"Tavneos\u00ae. EMA. Ficha t\u00e9cnica. [Internet]. [Accessed 22 April 2022]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1211605002\/FT_1211605002.html."},{"key":"10.1016\/j.nefroe.2025.01.001_bib0570","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0575","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ccm.2004.04.007","article-title":"Diffuse alveolar hemorrhage","volume":"25","author":"Collard","year":"2004","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0580","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","article-title":"Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"100","author":"Gulati","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0585","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11926-022-01064-8","article-title":"Is there still a role of plasma exchange in the current management of ANCA-associated vasculitides?","volume":"24","author":"Toyoda","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0590","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/acr.20605","article-title":"Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener\u2019s)","volume":"63","author":"Clowse","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0595","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/art.22660","article-title":"Gonad evaluation in male systemic lupus erythematosus","volume":"56","author":"Soares","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0600","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0605","first-page":"60","article-title":"Treatment of ANCA-associated systemic vasculitis","volume":"64","author":"Belmont","year":"2006","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0610","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/ndt\/16.10.2018","article-title":"The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review","volume":"16","author":"de Groot","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0615","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.reuma.2009.01.009","article-title":"Treatment of ANCA-associated systemic vasculitis","volume":"6","author":"R\u00faa-Figueroa Fern\u00e1ndez de Larrinoa","year":"2010","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0620","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.39011","article-title":"Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy","volume":"67","author":"Pagnoux","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0625","article-title":"Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: a retrospective study","volume":"6","author":"Ysermans","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0630","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0635","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ndt\/gfx378","article-title":"Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"34","author":"McAdoo","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037626","article-title":"Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides","volume":"7","author":"Venhoff","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0645","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061339","article-title":"ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial","volume":"12","author":"Dirikgil","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0650","doi-asserted-by":"crossref","first-page":"iii74","DOI":"10.1093\/rheumatology\/kez618","article-title":"Complications of therapy for ANCA-associated vasculitis","volume":"59","author":"Smith","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0655","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard.2010.145250","article-title":"Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials","volume":"70","author":"Heijl","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0660","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.25061","article-title":"Erratum: incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review","volume":"62","author":"Monach","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0665","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1177\/09612033221128740","article-title":"Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: a meta-analysis","volume":"31","author":"Ejaz","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0670","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ncprheum0770","article-title":"Therapy insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease","volume":"4","author":"Dooley","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0675","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0680","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018748","article-title":"Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial","volume":"7","author":"Furuta","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0685","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0690","doi-asserted-by":"crossref","first-page":"e1199","DOI":"10.34067\/KID.0000000000000257","article-title":"Intravenous methylprednisolone in induction therapy for ANCA-associated vasculitis: how low can we go?","volume":"4","author":"Oliva-Damaso","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0695","first-page":"SII33","article-title":"Implications for pathogenesis of patterns of injury in small- and medium-sized-vessel vasculitis","volume":"69 Suppl 2","author":"Jennette","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0700","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0705","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0710","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-015-0656-8","article-title":"Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis","volume":"17","author":"Chen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0715","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3389\/fimmu.2018.00559","article-title":"Complement factor H inhibits anti-neutrophil cytoplasmic autoantibody-induced neutrophil activation by interacting with neutrophils","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0720","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0725","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/blood-2010-05-283564","article-title":"Complement alternative pathway acts as a positive feedback amplification of neutrophil activation","volume":"117","author":"Camous","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0730","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0735","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.ki.5002103","article-title":"Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice","volume":"71","author":"Huugen","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0740","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0745","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0750","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","article-title":"Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan","volume":"8","author":"Cortazar","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0755","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ekir.2019.11.021","article-title":"Treatment of aggressive antineutrophil cytoplasmic antibody-associated vasculitis with eculizumab","volume":"5","author":"Huizenga","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0760","unstructured":"InflaRx N.V. InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study. GlobeNewswire News Room. [Internet], [Accessed 11 November 2023]. Available from: https:\/\/www.globenewswire.com\/en\/news-release\/2021\/05\/11\/2227670\/0\/en\/InflaRx-Announces-Positive-Topline-Results-for-Vilobelimab-from-the-U-S-Phase-II-ANCA-Associated-Vasculitis-IXPLORE-Study.html."},{"key":"10.1016\/j.nefroe.2025.01.001_bib0765","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ki.2010.472","article-title":"New pathophysiological insights and treatment of ANCA-associated vasculitis","volume":"79","author":"Wilde","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0770","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064597","article-title":"Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline","volume":"376","author":"Zeng","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0775","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00134-022-06793-z","article-title":"Plasma exchange in the intensive care unit: a narrative review","volume":"48","author":"Bauer","year":"2022","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0780","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.2013.131","article-title":"Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear","volume":"84","author":"Walsh","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0785","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0790","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0795","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1681\/ASN.2019111197","article-title":"Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease","volume":"31","author":"Casal Moura","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0800","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes","volume":"68","author":"Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0805","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2215\/CJN.10550620","article-title":"PEXIVAS: the end of plasmapheresis for ANCA-associated vasculitis?","volume":"16","author":"De Vriese","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0810","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2018.10.001","article-title":"ANCA Renal Risk Score: is prediction of end-stage renal disease at baseline possible?","volume":"94","author":"Kronbichler","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0815","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000324364","article-title":"Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis","volume":"33","author":"Han","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0820","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/ndt\/gfm780","article-title":"Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement","volume":"23","author":"Hu","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0825","article-title":"The role of mycophenolate mofetil for the induction of remission in ANCA-associated vasculitis: a meta-analysis","volume":"8","author":"Xiong","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0830","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1093\/ndt\/gfab357","article-title":"Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis","volume":"37","author":"Berti","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0835","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.06010809","article-title":"Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial","volume":"5","author":"Silva","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0840","doi-asserted-by":"crossref","first-page":"c100","DOI":"10.1159\/000089667","article-title":"Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis","volume":"102","author":"Koukoulaki","year":"2006","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0845","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2215\/CJN.11801018","article-title":"Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody-associated vasculitis: randomized, controlled trial","volume":"14","author":"Tuin","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0850","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/ndt\/gfi117","article-title":"A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis","volume":"20","author":"Joy","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0855","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/ard.2006.060301","article-title":"Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide","volume":"66","author":"Stassen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0860","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0865","doi-asserted-by":"crossref","first-page":"i132","DOI":"10.1093\/ndt\/gfv061","article-title":"Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital","volume":"30 Suppl 1","author":"Draibe","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0870","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0875","article-title":"LB004A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract]","volume":"35 Suppl 3","author":"Smith","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0880","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0885","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener\u2019s granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0890","doi-asserted-by":"crossref","first-page":"114","DOI":"10.55563\/clinexprheumatol\/ve38dj","article-title":"Efficacy of leflunomide in the treatment of vasculitis","volume":"39 Suppl 129","author":"Mustapha","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0895","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s10067-007-0643-9","article-title":"Rituximab for treatment-resistant extensive Wegener\u2019s granulomatosis--additive effects of a maintenance treatment with leflunomide","volume":"26","author":"Henes","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0900","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0905","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/ndt\/gfad237","article-title":"ANCA-associated vasculitis - treatment standard","volume":"39","author":"Chalkia","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0910","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0915","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/1744666X.2023.2162041","article-title":"Avacopan for the treatment of ANCA-associated vasculitis: an update","volume":"19","author":"Osman","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0920","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/art.41551","article-title":"Sustained remission of granulomatosis with polyangiitis after discontinuation of glucocorticoids and immunosuppressant therapy: data from the French vasculitis study group registry","volume":"73","author":"Pu\u00e9chal","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0925","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2021.11.036","article-title":"Compassionate use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"van Leeuwen","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0930","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/ard-2023-224816","article-title":"Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial","volume":"83","author":"Geetha","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0935","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/rheumatology\/keaa541","article-title":"Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models","volume":"60","author":"McClure","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0940","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/ar3797","article-title":"Progress in treatment of ANCA-associated vasculitis","volume":"14","author":"Smith","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0945","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1093\/ndt\/gfad090","article-title":"Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines\/recommendations","volume":"38","author":"Casal Moura","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0950","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2215\/CJN.03190321","article-title":"Disease activity and adverse events in patients with ANCA-associated vasculitides undergoing long-term dialysis","volume":"16","author":"Kauffmann","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0955","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.08290813","article-title":"Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure","volume":"9","author":"Lee","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0960","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152189","article-title":"Outcomes in ANCA-associated vasculitis patients with end-stage kidney disease on renal replacement therapy-a meta-analysis","volume":"60","author":"Pope","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0970","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000505660","article-title":"Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives","volume":"45","author":"Hruskova","year":"2020","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0975","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/qjmed\/hcu043","article-title":"Survival of patients with ANCA-associated vasculitis on chronic dialysis: data from the French REIN registry from 2002 to 2011","volume":"107","author":"Romeu","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0980","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40620-019-00642-x","article-title":"Kidney transplantation in ANCA-associated vasculitis","volume":"32","author":"Sagmeister","year":"2019","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0985","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/sj.ki.5002244","article-title":"Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression","volume":"71","author":"Gera","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0990","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1097\/TXD.0000000000000769","article-title":"Outcome of patients with small vessel vasculitis after renal transplantation: national database analysis","volume":"4","author":"El-Husseini","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.nefroe.2025.01.001_bib0995","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.autrev.2014.12.011","article-title":"State of the art: reproduction and pregnancy in rheumatic diseases","volume":"14","author":"\u00d8stensen","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1000","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/keq421","article-title":"Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies","volume":"50","author":"Pagnoux","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1005","doi-asserted-by":"crossref","first-page":"A447","DOI":"10.1016\/j.autrev.2011.11.019","article-title":"Pregnancy and vasculitis: a systematic review of the literature","volume":"11","author":"Gatto","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1010","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.autrev.2015.03.009","article-title":"Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies","volume":"14","author":"Fredi","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1015","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1080\/14767058.2019.1671329","article-title":"Pregnancy outcomes in women with primary systemic vasculitis: a retrospective study","volume":"34","author":"Nguyen","year":"2021","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/ckj\/sfy011","article-title":"De novo antineutrophil cytoplasmic antibody-associated vasculitis in pregnancy: a systematic review on maternal, pregnancy and fetal outcomes","volume":"11","author":"Veltri","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1025","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1191\/0961203304lu1098oa","article-title":"Pregnancy in rare autoimmune rheumatic diseases: UCTD, MCTD, myositis, systemic vasculitis and Be\u00e7het disease","volume":"13","author":"Doria","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/ki.2014.329","article-title":"Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis","volume":"87","author":"Croft","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1035","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/acr.21983","article-title":"Vasculitis Clinical Research Consortium Pregnancy outcomes among patients with vasculitis","volume":"65","author":"Clowse","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1040","doi-asserted-by":"crossref","first-page":"rkaa074","DOI":"10.1093\/rap\/rkaa074","article-title":"Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series","volume":"5","author":"Perrotta","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1045","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/1756-185X.13342","article-title":"Successful treatment outcomes in pregnant patients with ANCA-associated vasculitides: a systematic review of literature","volume":"21","author":"Singh","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1055","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1060","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41584-022-00842-z","article-title":"A comprehensive guide for managing the reproductive health of patients with vasculitis","volume":"18","author":"Sims","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1065","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/rheumatology\/kev405","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part II: analgesics and other drugs used in rheumatology practice","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1070","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/rheumatology\/kev018","article-title":"Pregnancy outcome in patients with systemic vasculitis: a single-centre matched case-control study","volume":"54","author":"Sangle","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1075","article-title":"The vasculitis pregnancy registry (V-PREG): information from the first 3 years","volume":"71 Suppl 10","author":"Golenbiewski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1080","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2215\/CJN.04760422","article-title":"Rituximab in the frail and elderly with severe ANCA-associated GN","volume":"17","author":"Brix","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1085","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019173","article-title":"Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective observational study","volume":"99","author":"Waki","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1090","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.2215\/CJN.00480115","article-title":"Outcome and treatment of elderly patients with ANCA-associated vasculitis","volume":"10","author":"Weiner","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13075-020-02341-6","article-title":"Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies","volume":"22","author":"Sada","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1100","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/rheumatology\/kez388","article-title":"Long-term outcomes in elderly patients with ANCA-associated vasculitis","volume":"59","author":"McGovern","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1105","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1080\/14397595.2016.1226468","volume":"27","author":"Watanabe-Imai","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40266-018-0617-4","article-title":"Aging in primary systemic vasculitis: implications for diagnosis, clinical manifestations, and management","volume":"36","author":"Berti","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1115","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s10067-023-06644-2","article-title":"Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly","volume":"42","author":"Aqeel","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1120","first-page":"6","article-title":"ANCA and anti-MBG double-positive vasculitis: an update on the clinical and therapeutic specificities and comparison with the two eponymous vasculitis","volume":"41","author":"Philip","year":"2020","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1125","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1681\/ASN.2006111210","article-title":"Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies","volume":"18","author":"Yang","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2215\/CJN.05270515","article-title":"Autoantibodies against linear epitopes of myeloperoxidase in anti-glomerular basement membrane disease","volume":"11","author":"Li","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/omcr\/omw026","article-title":"Sequential occurrence of anti-glomerular basement membrane disease 9 years after anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"2016","author":"Chan","year":"2016","journal-title":"Oxf Med Case Reports"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1140","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.2169\/internalmedicine.8757-16","article-title":"The sequential development of antiglomerular basement membrane nephritis and myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis","volume":"56","author":"Ohashi","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1145","first-page":"251","article-title":"Sequential development of systemic vasculitis with anti-neutrophil cytoplasmic antibodies complicating anti-glomerular basement membrane disease","volume":"32","author":"O\u2019Donoghue","year":"1989","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1150","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","article-title":"Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients","volume":"92","author":"McAdoo","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.ajkd.2005.05.003","article-title":"Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis","volume":"46","author":"Rutgers","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1160","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1523-1755.2004.00917.x","article-title":"Clinical features and outcome of patients with both ANCA and anti-GBM antibodies","volume":"66","author":"Levy","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1165","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1681\/ASN.V83376","article-title":"Comparison of anti-GBM antibodies in sera with or without ANCA","volume":"8","author":"Hellmark","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1170","doi-asserted-by":"crossref","first-page":"c56","DOI":"10.1159\/000107803","article-title":"Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies","volume":"107","author":"Zhao","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1175","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017801","article-title":"Rituximab in treatment of anti-GBM antibody glomerulonephritis: a case report and literature review","volume":"98","author":"Uematsu-Uchida","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/1744-9987.13718","article-title":"Anti-glomerular basement membrane disease (Goodpasture disease): from pathogenesis to plasma exchange to IdeS","volume":"26","author":"Shin","year":"2022","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000515388","article-title":"Recurrent nephritis and\/or pulmonary hemorrhage in patients with anti-glomerular basement membrane disease with and without ANCA positivity","volume":"1","author":"Droz","year":"2021","journal-title":"Glomerular Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1190","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1046\/j.1523-1755.2003.00843.x","article-title":"Rapidly progressive crescentic glomerulonephritis","volume":"63","author":"Jennette","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1195","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/art.40034","article-title":"Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"69","author":"Merkel","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1681\/ASN.2006091021","article-title":"Antineutrophil cytoplasmic autoantibody-negative Pauci-immune crescentic glomerulonephritis","volume":"18","author":"Chen","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1205","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1523-1755.1998.00807.x","article-title":"Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC\/BCR Project for ANCA Assay Standardization","volume":"53","author":"Hagen","year":"1998","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1210","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/ndt\/15.10.1593","article-title":"Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study","volume":"15","author":"Hedger","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1215","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrneph.2009.67","article-title":"ANCA-negative pauci-immune crescentic glomerulonephritis","volume":"5","author":"Chen","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1220","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1093\/ndt\/gfh830","article-title":"ANCA-negative pauci-immune renal vasculitis: histology and outcome","volume":"20","author":"Eisenberger","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1225","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1002\/art.39812","article-title":"Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener\u2019s): distinct patient subsets","volume":"68","author":"Miloslavsky","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1230","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1136\/ard.2010.130203","article-title":"Prospective long-term follow-up of patients with localised Wegener\u2019s granulomatosis: does it occur as persistent disease stage?","volume":"69","author":"Holle","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1235","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002160","article-title":"Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry","volume":"8","author":"Pu\u00e9chal","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1240","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105540","article-title":"Traditional and disease-related cardiovascular risk factors in ANCA-associated vasculitis: a prospective, two-centre cohort study","volume":"90","author":"Vegting","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1245","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jep.12709","article-title":"Management of cardiovascular risk factors in patients with ANCA-associated vasculitis","volume":"23","author":"Bramlage","year":"2017","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1250","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3899\/jrheum.220851.C1","article-title":"Traditional and disease specific risk factors for cardiovascular events in ANCA-associated vasculitis: a multinational retrospective study","volume":"50","author":"Moiseev","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1255","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.mayocp.2018.02.010","article-title":"Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20-year population-based cohort study","volume":"93","author":"Berti","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1260","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1265","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1093\/rheumatology\/kez589","article-title":"All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type","volume":"59","author":"Wallace","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1270","doi-asserted-by":"crossref","first-page":"iii79","DOI":"10.1093\/rheumatology\/kez617","article-title":"Comorbidities in ANCA-associated vasculitis","volume":"59","author":"Kronbichler","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1275","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/rheumatology\/key285","article-title":"Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides","volume":"58","author":"Garen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1280","doi-asserted-by":"crossref","first-page":"i60","DOI":"10.1093\/ndt\/gfu392","article-title":"The long-term outcomes of systemic vasculitis","volume":"30 Suppl 1","author":"Westman","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1285","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1290","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2016.06.005","article-title":"Left ventricular diastolic dysfunction and increased left ventricular mass index related to pulmonary hypertension in patients with systemic autoimmune disease without pericardial effusion","volume":"220","author":"Sugiura","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1295","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s10067-017-3868-2","article-title":"Echocardiographic features in patients with ANCA-associated vasculitis within 3 months before and after diagnosis","volume":"36","author":"Ahn","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1300","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1305","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/ndt\/gfz137","article-title":"SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA","volume":"35","author":"Sarafidis","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1310","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/ard.2009.109389","article-title":"Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis","volume":"69","author":"Little","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1315","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","article-title":"Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis","volume":"77","author":"Kronbichler","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1320","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12882-018-0933-2","article-title":"Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study","volume":"19","author":"Yang","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1325","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3899\/jrheum.160909","article-title":"Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"44","author":"Mohammad","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1330","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3899\/jrheum.190065","article-title":"Prevalence and risk factors for major infections in patients with antineutrophil cytoplasmic antibody-associated vasculitis: influence on the disease outcome","volume":"47","author":"Garcia-Vives","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1335","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/ard-2022-223401","article-title":"Risk factors for serious infections in ANCA-associated vasculitis","volume":"82","author":"Odler","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1340","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.reuma.2021.04.006","article-title":"Recommendations for prevention of infection in systemic autoimmune rheumatic diseases","volume":"18","author":"R\u00faa-Figueroa Fern\u00e1ndez de Larrinoa","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1345","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1350","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/ndt\/gfm640","article-title":"Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis","volume":"23","author":"Stassen","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1355","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1360","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.vaccine.2017.05.044","article-title":"Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy","volume":"35","author":"Nived","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1365","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1370","first-page":"3224","article-title":"Association between hypogammaglobulinaemia and severe infections during induction therapy in ANCA-associated vasculitis: from J-CANVAS study","author":"Omura","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1375","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/rheumatology\/keac716","article-title":"Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study","volume":"62","author":"Podest\u00e0","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1380","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/rheumatology\/key394","article-title":"Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases","volume":"58","author":"Wijetilleka","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1385","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.42030","article-title":"SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis","volume":"74","author":"Conway","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1390","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40620-020-00881-3","article-title":"The impact of COVID-19 pandemic on patients with ANCA associated vasculitis","volume":"34","author":"Kant","year":"2021","journal-title":"J Nephrol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1395","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41584-022-00755-x","article-title":"COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations","volume":"18","author":"Grainger","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1400","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1136\/annrheumdis-2021-222006","article-title":"EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update","volume":"81","author":"Landew\u00e9","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1405","first-page":"922","article-title":"Multicentre case-control study evaluating the safety of anti-SARS-CoV-2 vaccines in a cohort of patients with systemic vasculitis","volume":"41","author":"Simoncelli","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1410","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1415","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1111\/febs.16662","article-title":"A guide to COVID-19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS-CoV-2 infection","volume":"291","author":"Brady","year":"2022","journal-title":"FEBS J"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1420","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2013-203927","article-title":"Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials","volume":"74","author":"Robson","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1425","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.3390\/ijms20235867","article-title":"Osteoporosis in rheumatic diseases","volume":"20","author":"Adami","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1430","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.3899\/jrheum.151151","article-title":"Comorbidities in patients with antineutrophil cytoplasmic antibody-associated vasculitis versus the general population","volume":"43","author":"Englund","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1435","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/art.41557","article-title":"Multimorbidity in antineutrophil cytoplasmic antibody-associated vasculitis: results from a longitudinal, multicenter data linkage study","volume":"73","author":"Sarica","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1440","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/rheumatology\/keaa594","article-title":"Comparison of fracture risk between proton pump inhibitors and histamine-2 receptor antagonists in ANCA-associated vasculitis patients: a nested case-control study","volume":"60","author":"Miyano","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1445","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s198-002-8341-z","article-title":"Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study","volume":"13","author":"Boomsma","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1450","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1455","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/ndt\/gfaa310","article-title":"Glucocorticoid-free treatment of severe ANCA-associated vasculitis","volume":"36","author":"Farrah","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1460","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases","volume":"72","author":"Duru","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefroe.2025.01.001_bib1465","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.806361","article-title":"The impact of high dose glucocorticoids on bone health and fracture risk in systemic vasculitides","volume":"13","author":"Box","year":"2022","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S201325142500001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S201325142500001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:41:01Z","timestamp":1762598461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S201325142500001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":293,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S201325142500001X"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.01.001","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations for the diagnosis and treatment of anti-neutrophil cytoplasmic autoantibody associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2024.07.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}